{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T16:32:02Z","timestamp":1773160322291,"version":"3.50.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T00:00:00Z","timestamp":1645747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T00:00:00Z","timestamp":1645747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100005847","name":"Health and Medical Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005847","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s00213-022-06088-7","type":"journal-article","created":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T02:02:31Z","timestamp":1645754551000},"page":"2133-2141","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Striatal dopamine synthesis capacity and its association with negative symptoms upon resolution of positive symptoms in first-episode schizophrenia and delusional disorder"],"prefix":"10.1007","volume":"239","author":[{"given":"Stephanie M. Y.","family":"Wong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y. N.","family":"Suen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte W. C.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherry K. W.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christy L. M.","family":"Hui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. C.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edwin H. M.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Calvin P. W.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garrett C. L.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gladys Goh","family":"Lo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric Y. L.","family":"Leung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul K. M. Au","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sirong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William G.","family":"Honer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry K. F.","family":"Mak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. C.","family":"Sham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J.","family":"McKenna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edith","family":"Pomarol-Clotet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mattia","family":"Veronese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver D.","family":"Howes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric Y. H.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,25]]},"reference":[{"key":"6088_CR1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1192\/S0007125000292581","volume":"22","author":"D Addington","year":"1993","unstructured":"Addington D, Addington J, Maticka-Tyndale E (1993) Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry Suppl 22:39\u201344","journal-title":"Br J Psychiatry Suppl"},{"key":"6088_CR2","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders (5th ed.). Washington, DC: American Psychiatric Publishing","DOI":"10.1176\/appi.books.9780890425596"},{"key":"6088_CR3","unstructured":"Andreasen NC (1984a). Scale for the assessment of negative symptoms (SANS. Iowa City: University of Iowa"},{"key":"6088_CR4","unstructured":"Andreasen NC (1984b). Scale for the assessment of positive symptoms (SAPS. Iowa City: University of Iowa"},{"issue":"6","key":"6088_CR5","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1093\/brain\/awz093","volume":"142","author":"M Avram","year":"2019","unstructured":"Avram M, Brandl F, Cabello J, Leucht C, Scherr M, Mustafa M et al (2019) Reduced striatal dopamine synthesis capacity in patients with schizophrenia during remission of positive symptoms. Brain 142(6):1813\u20131826","journal-title":"Brain"},{"key":"6088_CR6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.schres.2020.03.061","volume":"220","author":"SKW Chan","year":"2020","unstructured":"Chan SKW, Chan HYV, Pang HH, Hui CLM, Suen YN, Chang WC et al (2020) Ten-year trajectory and outcomes of negative symptoms of patients with first-episode schizophrenia spectrum disorders. Schizophr Res 220:85\u201391","journal-title":"Schizophr Res"},{"issue":"2\u20133","key":"6088_CR7","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.schres.2016.01.004","volume":"170","author":"WC Chang","year":"2016","unstructured":"Chang WC, Hui CLM, Chan SKW, Lee EHM, Chen EYH (2016) Impact of avolition and cognitive impairment on functional outcome in first-episode schizophrenia-spectrum disorder: a prospective one-year follow-up study. Schizophr Res 170(2\u20133):318\u2013321","journal-title":"Schizophr Res"},{"issue":"11","key":"6088_CR8","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1038\/s41386-020-0740-x","volume":"45","author":"PWC Cheng","year":"2020","unstructured":"Cheng PWC, Chang WC, Lo GG, Chan KWS, Lee HME, Hui LMC et al (2020) The role of dopamine dysregulation and evidence for the transdiagnostic nature of elevated dopamine synthesis in psychosis: a positron emission tomography (PET) study comparing schizophrenia, delusional disorder, and other psychotic disorders. Neuropsychopharmacology 45(11):1870\u20131876","journal-title":"Neuropsychopharmacology"},{"key":"6088_CR9","unstructured":"Cohen J (1988) Statistical power analysis for the behavioral sciences. 2nd ed. New York: American Press"},{"key":"6088_CR10","doi-asserted-by":"publisher","first-page":"632","DOI":"10.3389\/fnins.2020.00632","volume":"14","author":"G Collo","year":"2020","unstructured":"Collo G, Mucci A, Giordano GM, Merlo Pich E, Galderisi S (2020) Negative symptoms of schizophrenia and dopaminergic transmission: translational models and perspectives opened by iPSC techniques. Front Neurosci 14:632","journal-title":"Front Neurosci"},{"key":"6088_CR11","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2147\/NDT.S225643","volume":"16","author":"CU Correll","year":"2020","unstructured":"Correll CU, Schooler NR (2020) Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment. Neuropsychiatr Dis Treat 16:519\u2013534","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"2","key":"6088_CR12","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0920-9964(96)00102-8","volume":"23","author":"M-H Dao-Castellana","year":"1997","unstructured":"Dao-Castellana M-H, Paill\u00e8re-Martinot M-L, Hantraye P, Attar-L\u00e9vy D, R\u00e9my P, Crouzel C et al (1997) Presynaptic dopaminergic function in the striatum of schizophrenic patients. Schizophr Res 23(2):167\u2013174","journal-title":"Schizophr Res"},{"issue":"4","key":"6088_CR13","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1038\/s41380-019-0570-6","volume":"26","author":"E D\u2019Ambrosio","year":"2021","unstructured":"D\u2019Ambrosio E, Jauhar S, Kim S, Veronese M, Rogdaki M, Pepper F et al (2021) The relationship between grey matter volume and striatal dopamine function in psychosis: a multimodal 18 F-DOPA PET and voxel-based morphometry study. Mol Psychiatry 26(4):1332\u20131345","journal-title":"Mol Psychiatry"},{"issue":"11","key":"6088_CR14","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1176\/appi.ajp.2012.12010144","volume":"169","author":"A Demjaha","year":"2012","unstructured":"Demjaha A, Murray RM, McGuire PK, Kapur S, Howes OD (2012) Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. Am J Psychiatry 169(11):1203\u20131210","journal-title":"Am J Psychiatry"},{"key":"6088_CR15","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1176\/jnp.8.3.281","volume":"8","author":"JD Evans","year":"1996","unstructured":"Evans JD, Paulsen JS, Jackuelyn M, Harris MD, Heaton RK, Jeste DV (1996) A clinical and neuropsychological comparison of delusional disorder and schizophrenia. J Neuropsychiatry Clin Neurosci 8:281\u2013286","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"7","key":"6088_CR16","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.eurpsy.2014.01.007","volume":"29","author":"G Fervaha","year":"2014","unstructured":"Fervaha G, Foussias G, Agid O, Remington G (2014) Impact of primary negative symptoms on functional outcomes in schizophrenia. Eur Psychiatry 29(7):449\u2013455","journal-title":"Eur Psychiatry"},{"issue":"1","key":"6088_CR17","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.schres.2011.06.026","volume":"132","author":"G Foussias","year":"2011","unstructured":"Foussias G, Mann S, Zakzanis KK, van Reekum R, Agid O, Remington G (2011) Prediction of longitudinal functional outcomes in schizophrenia: the impact of baseline motivational deficits. Schizophr Res 132(1):24\u201327","journal-title":"Schizophr Res"},{"issue":"3","key":"6088_CR18","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1093\/schbul\/sbq031","volume":"36","author":"A Heinz","year":"2010","unstructured":"Heinz A, Schlagenhauf F (2010) Dopaminergic dysfunction in schizophrenia: salience attribution revisited. Schizophr Bull 36(3):472\u2013485","journal-title":"Schizophr Bull"},{"issue":"8983","key":"6088_CR19","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/S0140-6736(95)91801-9","volume":"346","author":"J Hietala","year":"1995","unstructured":"Hietala J, Syv\u00e4lahti E, Vuorio K, R\u00e4kk\u00f6l\u00e4inen V, Bergman J, Haaparanta M et al (1995) Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet 346(8983):1130\u20131131","journal-title":"Lancet"},{"issue":"1","key":"6088_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1192\/bjp.bp.113.138578","volume":"205","author":"OD Howes","year":"2014","unstructured":"Howes OD, Kapur S (2014) A neurobiological hypothesis for the classification of schizophrenia: type a (hyperdopaminergic) and type B (normodopaminergic). Br J Psychiatry 205(1):1\u20133","journal-title":"Br J Psychiatry"},{"issue":"9929","key":"6088_CR21","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/S0140-6736(13)62036-X","volume":"383","author":"OD Howes","year":"2014","unstructured":"Howes OD, Murray RM (2014) Schizophrenia: an integrated socio developmental-cognitive model. Lancet 383(9929):1677\u201387","journal-title":"Lancet"},{"issue":"1","key":"6088_CR22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1001\/archgenpsychiatry.2008.514","volume":"66","author":"OD Howes","year":"2009","unstructured":"Howes OD, Montgomery AJ, Asselin M-C, Murray RM, Valli I, Tabraham P et al (2009) Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry 66(1):13\u201320","journal-title":"Arch Gen Psychiatry"},{"issue":"12","key":"6088_CR23","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1176\/appi.ajp.2011.11010160","volume":"168","author":"OD Howes","year":"2011","unstructured":"Howes OD, Bose SK, Turkheimer F, Valli I, Egerton A, Valmaggia LR et al (2011) Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study. Am J Psychiatry 168(12):1311\u20131317","journal-title":"Am J Psychiatry"},{"issue":"8","key":"6088_CR24","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1001\/archgenpsychiatry.2012.169","volume":"69","author":"OD Howes","year":"2012","unstructured":"Howes OD, Kambeitz J, Kim E, Stahl D, Slifstein M, Abi-Dargham A et al (2012) The nature of dopamine dysfunction in schizophrenia and what this means for treatment: meta-analysis of imaging studies. Arch Gen Psychiatry 69(8):776\u2013786","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"6088_CR25","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1177\/0269881114563634","volume":"29","author":"O Howes","year":"2015","unstructured":"Howes O, McCutcheon R, Stone J (2015) Glutamate and dopamine in schizophrenia: an update for the 21st century. J Psychopharmacol 29(2):97\u2013115","journal-title":"J Psychopharmacol"},{"issue":"14","key":"6088_CR26","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1017\/S0033291715001051","volume":"45","author":"CLM Hui","year":"2015","unstructured":"Hui CLM, Lee EHM, Chang WC, Chan SKW, Lin J, Xu JQ et al (2015) Delusional disorder and schizophrenia: a comparison of the neurocognitive and clinical characteristics in first-episode patients. Psychol Med 45(14):3085\u20133095","journal-title":"Psychol Med"},{"issue":"2","key":"6088_CR27","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1038\/tp.2016.270","volume":"7","author":"S Jauhar","year":"2017","unstructured":"Jauhar S, Veronese M, Rogdaki M, Bloomfield M, Natesan S, Turkheimer F et al (2017) Regulation of dopaminergic function: an [18 F]-DOPA PET apomorphine challenge study in humans. Transl Psychiatry 7(2):1027\u20131027","journal-title":"Transl Psychiatry"},{"issue":"10","key":"6088_CR28","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1038\/s41380-018-0042-4","volume":"24","author":"S Jauhar","year":"2019","unstructured":"Jauhar S, Veronese M, Nour MM, Rogdaki M, Hathway P, Turkheimer FE et al (2019) Determinants of treatment response in first-episode psychosis: an 18 F-DOPA PET study. Mol Psychiatry 24(10):1502\u20131512","journal-title":"Mol Psychiatry"},{"key":"6088_CR29","doi-asserted-by":"crossref","unstructured":"Kaar SJ, Natesan S, Mccutcheon R, Howes OD (2020) Antipsychotics: mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology. Neuropharmacology 172:107704","DOI":"10.1016\/j.neuropharm.2019.107704"},{"issue":"6","key":"6088_CR30","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1093\/schbul\/sbaa055","volume":"46","author":"T Katthagen","year":"2020","unstructured":"Katthagen T, Kaminski J, Heinz A, Buchert R, Schlagenhauf F (2020) Striatal dopamine and reward prediction error signaling in unmedicated schizophrenia patients. Schizophr Bull 46(6):1535\u20131546","journal-title":"Schizophr Bull"},{"issue":"3","key":"6088_CR31","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1176\/ajp.156.3.406","volume":"156","author":"ME Kelley","year":"1999","unstructured":"Kelley ME, van Kammen DP, Allen DN (1999) Empirical validation of primary negative symptoms: independence from effects of medication and psychosis. Am J Psychiatry 156(3):406\u2013411","journal-title":"Am J Psychiatry"},{"issue":"4","key":"6088_CR32","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/npp.2016.258","volume":"42","author":"E Kim","year":"2017","unstructured":"Kim E, Howes OD, Veronese M, Beck K, Seo S, Park JW et al (2017) Presynaptic dopamine capacity in patients with treatment-resistant schizophrenia taking clozapine: an [18 F] DOPA PET study. Neuropsychopharmacology 42(4):941\u2013950","journal-title":"Neuropsychopharmacology"},{"key":"6088_CR33","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.schres.2016.05.003","volume":"186","author":"M Kirschner","year":"2017","unstructured":"Kirschner M, Aleman A, Kaiser S (2017) Secondary negative symptoms\u2014a review of mechanisms, assessment and treatment. Schizophr Research 186:29\u201338","journal-title":"Schizophr Research"},{"issue":"3","key":"6088_CR34","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/schbul\/sbq125","volume":"38","author":"A Marneros","year":"2012","unstructured":"Marneros A, Pillmann F, Wustmann T (2012) Delusional disorders\u2014are they simply paranoid schizophrenia? Schizophr Bulletin 38(3):561\u2013568","journal-title":"Schizophr Bulletin"},{"issue":"3","key":"6088_CR35","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.tins.2018.12.004","volume":"42","author":"RA McCutcheon","year":"2019","unstructured":"McCutcheon RA, Abi-Dargham A, Howes OD (2019) Schizophrenia, dopamine and the striatum: from biology to symptoms. Trends Neurosci 42(3):205\u2013220","journal-title":"Trends Neurosci"},{"issue":"6","key":"6088_CR36","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1093\/schbul\/sbx180","volume":"44","author":"R McCutcheon","year":"2018","unstructured":"McCutcheon R, Beck K, Jauhar S, Howes OD (2018) Defining the locus of dopaminergic dysfunction in schizophrenia: a meta-analysis and test of the mesolimbic hypothesis. Schizophr Bull 44(6):1301\u20131311","journal-title":"Schizophr Bull"},{"issue":"11","key":"6088_CR37","first-page":"1040","volume":"5","author":"RA McCutcheon","year":"2020","unstructured":"McCutcheon RA, Jauhar S, Pepper F, Nour MM, Rogdaki M, Veronese M et al (2020) The topography of striatal dopamine and symptoms in psychosis: an integrative positron emission tomography and magnetic resonance imaging study. Biol Psychiatry Cogn Neurosci Neuroimaging 5(11):1040\u20131051","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"issue":"2","key":"6088_CR38","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1001\/archpsyc.61.2.134","volume":"61","author":"S McGowan","year":"2004","unstructured":"McGowan S, Lawrence AD, Sales T, Quested D, Grasby P (2004) Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F] fluorodopa study. Arch Gen Psychiatry 61(2):134\u2013142","journal-title":"Arch Gen Psychiatry"},{"issue":"6","key":"6088_CR39","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/S0893-133X(01)00421-3","volume":"26","author":"K Morimoto","year":"2002","unstructured":"Morimoto K, Miyatake R, Nakamura M, Watanabe T, Hirao T, Suwaki H (2002) Delusional disorder: molecular genetic evidence for dopamine psychosis. Neuropsychopharmacology 26(6):794\u2013801","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"6088_CR40","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1177\/0706743717706347","volume":"63","author":"JE Mu\u00f1oz-Negro","year":"2018","unstructured":"Mu\u00f1oz-Negro JE, Ib\u00e1\u00f1ez-Casas I, de Portugal E, Lozano-Guti\u00e9rrez V, Mart\u00ednez-Leal R, Cervilla JA (2018) A psychopathological comparison between delusional disorder and schizophrenia. Can J Psychiatry 63(1):12\u201319","journal-title":"Can J Psychiatry"},{"issue":"1\u20133","key":"6088_CR41","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.schres.2015.10.039","volume":"169","author":"JE Mu\u00f1oz-Negro","year":"2015","unstructured":"Mu\u00f1oz-Negro JE, Ibanez-Casas I, de Portugal E, Ochoa S, Dolz M, Haro JM et al (2015) A dimensional comparison between delusional disorder, schizophrenia and schizoaffective disorder. Schizophr Res 169(1\u20133):248\u2013254","journal-title":"Schizophr Res"},{"issue":"9","key":"6088_CR42","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1176\/appi.ajp.157.9.1461","volume":"157","author":"V Peralta","year":"2000","unstructured":"Peralta V, Cuesta MJ, Martinez-Larrea A, Serrano JF (2000) Differentiating primary from secondary negative symptoms in schizophrenia: a study of neuroleptic-naive patients before and after treatment. Am J Psychiatry 157(9):1461\u20131466","journal-title":"Am J Psychiatry"},{"issue":"3","key":"6088_CR43","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/0277-9536(88)90397-8","volume":"26","author":"JW Pennebaker","year":"1988","unstructured":"Pennebaker JW, Susman JR (1988) Disclosure of traumas and psychosomatic processes. Soc Sci Med 26(3):327\u2013332","journal-title":"Soc Sci Med"},{"key":"6088_CR44","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.schres.2018.08.036","volume":"204","author":"T Rowland","year":"2019","unstructured":"Rowland T, Birchwood M, Singh S, Freemantle N, Everard L, Jones P et al (2019) Short-term outcome of first episode delusional disorder in an early intervention population. Schizophr Res 204:72\u201379","journal-title":"Schizophr Res"},{"issue":"9859","key":"6088_CR45","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1016\/S0140-6736(12)61680-8","volume":"380","author":"JA Salomon","year":"2012","unstructured":"Salomon JA, Vos T, Hogan DR, Gagnon M, Naghavi M, Mokdad A, Begum N, Shah R, Karyana M, Kosen S, Farje MR (2012) Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet 380(9859):2129\u20132143","journal-title":"Lancet"},{"issue":"5","key":"6088_CR46","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.neuron.2010.02.014","volume":"65","author":"EH Simpson","year":"2010","unstructured":"Simpson EH, Kellendonk C, Kandel E (2010) A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia. Neuron 65(5):585\u2013596","journal-title":"Neuron"},{"key":"6088_CR47","doi-asserted-by":"crossref","unstructured":"Skelton M, Khokhar WA, Thacker SP (2015) Treatments for delusional disorder. Cochrane Database Syst Rev (5)","DOI":"10.1002\/14651858.CD009785.pub2"},{"issue":"11","key":"6088_CR48","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1017\/S0033291711000341","volume":"41","author":"P Shotbolt","year":"2011","unstructured":"Shotbolt P, Stokes PR, Owens SF, Toulopoulou T, Picchioni MM, Bose SK et al (2011) Striatal dopamine synthesis capacity in twins discordant for schizophrenia. Psychol Med 41(11):2331\u20132338","journal-title":"Psychol Med"},{"issue":"1","key":"6088_CR49","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41537-021-00145-4","volume":"7","author":"GP Strauss","year":"2021","unstructured":"Strauss GP, Bartolomeo LA, Harvey PD (2021) Avolition as the core negative symptom in schizophrenia: relevance to pharmacological treatment development. NPJ Schizophr 7(1):16","journal-title":"NPJ Schizophr"},{"issue":"3","key":"6088_CR50","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/j.1751-7893.2010.00193.x","volume":"4","author":"JY Tang","year":"2010","unstructured":"Tang JY, Wong GH, Hui CL, Lam MM, Chiu CP, Chan SK et al (2010) Early intervention for psychosis in Hong Kong\u2013the EASY programme. Early Interv Psychiatry 4(3):214\u2013219","journal-title":"Early Interv Psychiatry"},{"issue":"2\u20133","key":"6088_CR51","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.schres.2014.10.043","volume":"161","author":"J Ventura","year":"2015","unstructured":"Ventura J, Subotnik KL, Gitlin MJ, Gretchen-Doorly D, Ered A, Villa KF et al (2015) Negative symptoms and functioning during the first year after a recent onset of schizophrenia and 8 years later. Schizophr Res 161(2\u20133):407\u2013413","journal-title":"Schizophr Res"},{"key":"6088_CR52","doi-asserted-by":"crossref","unstructured":"Veronese M, Santangelo B, Jauhar S, D\u2019Ambrosio E, Demjaha A, Salimbeni H, et al. A potential biomarker for treatment stratification in psychosis: evaluation of an [18 F] FDOPA PET imaging approach. Neuropsychopharmacology. 2021;1122\u201332.","DOI":"10.1038\/s41386-020-00866-7"},{"issue":"6","key":"6088_CR53","doi-asserted-by":"publisher","first-page":"663","DOI":"10.4088\/JCP.v64n0607","volume":"64","author":"SW Woods","year":"2003","unstructured":"Woods SW (2003) Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 64(6):663\u2013667","journal-title":"J Clin Psychiatry"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-022-06088-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-022-06088-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-022-06088-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T22:01:19Z","timestamp":1674856879000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-022-06088-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,25]]},"references-count":53,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["6088"],"URL":"https:\/\/doi.org\/10.1007\/s00213-022-06088-7","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,25]]},"assertion":[{"value":"29 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"EYHC has received speaker honoraria from Otsuka and DSK BioPharma, research funding from Otsuka, participated in paid advisory boards for Janssen and DSK BioPharma, and received funding to attend conferences from Otsuka and DSK BioPharma. WGH has been a consultant to AbbVie and Translational Life Sciences in the past year. ODH is a part-time employee of H Lundbeck A\/s. He has received investigator-initiated research funding from and\/or participated in advisory\/speaker meetings organised by Angellini, Autifony, Biogen, Boehringer-Ingelheim, Eli Lilly, Heptares, Global Medical Education, Invicro, Jansenn, Lundbeck, Neurocrine, Otsuka, Sunovion, Recordati, Roche, and Viatris\/Mylan. Neither does ODH or his family have holdings or financial stake in any pharmaceutical company. ODH has a patent for the use of dopaminergic imaging. Other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}